Immunitybio (IBRX) had the highest return between May 10, 2017 and June 30, 2017 by a mid-cap US stock, returning 139.4%.
| ASSET | DATE | % RETURN |
|---|---|---|
Immunitybio (IBRX) | 5/10/2017 - 6/30/2017 | 139.43% |
Option Care Health (OPCH) | 5/10/2017 - 6/30/2017 | 62.57% |
PTC Therapeutics (PTCT) | 5/10/2017 - 6/30/2017 | 55.47% |
Catalyst Pharmaceuticals (CPRX) | 5/10/2017 - 6/30/2017 | 54.19% |
Appian (APPN) | 5/10/2017 - 6/30/2017 | 51.25% |
Amicus Therapeutics (FOLD) | 5/10/2017 - 6/30/2017 | 50.97% |
Sunrun (RUN) | 5/10/2017 - 6/30/2017 | 45.9% |
Novocure (NVCR) | 5/10/2017 - 6/30/2017 | 42.39% |
Modine Manufacturing (MOD) | 5/10/2017 - 6/30/2017 | 33.47% |
Vericel Corp Ord (VCEL) | 5/10/2017 - 6/30/2017 | 32% |
Etsy (ETSY) | 5/10/2017 - 6/30/2017 | 30.1% |
IAMGold (IAG) | 5/10/2017 - 6/30/2017 | 29.65% |
AeroVironment (AVAV) | 5/10/2017 - 6/30/2017 | 29.62% |
Laureate Education (LAUR) | 5/10/2017 - 6/30/2017 | 29.47% |
Axsome Therapeutics (AXSM) | 5/10/2017 - 6/30/2017 | 29.41% |
RadNet (RDNT) | 5/10/2017 - 6/30/2017 | 29.17% |
Kratos Defense & Security Solutions (KTOS) | 5/10/2017 - 6/30/2017 | 29.02% |
iRhythm Technologies (IRTC) | 5/10/2017 - 6/30/2017 | 28.64% |
Pegasystems (PEGA) | 5/10/2017 - 6/30/2017 | 26.47% |
Surgery Partners (SGRY) | 5/10/2017 - 6/30/2017 | 26.39% |
Impinj (PI) | 5/10/2017 - 6/30/2017 | 25.1% |
Blueprint Medicines (BPMC) | 5/10/2017 - 6/30/2017 | 24.68% |
Wayfair (W) | 5/10/2017 - 6/30/2017 | 24.62% |
B2Gold (BTG) | 5/10/2017 - 6/30/2017 | 23.25% |
CleanSpark (CLSK) | 5/10/2017 - 6/30/2017 | 23.21% |
Mid-cap stocks are treated as having a market cap between $2B and $10B.
